'Designer Babies': The Ultimate Privileged Elite?
By Heather Long,
Guardian
| 07. 09. 2013
When the world looks back at how the "designer babies" trend began, they will see an innocent start.
A Philadelphia couple who had gone through the physical and emotional marathon of trying to have a child turned to intra-uterine insemination and ultimately IVF. Like any rational people, they wanted to do everything to increase their chances that IVF would work. In this case, they sent the embryos to an Oxford lab, which ran a kind of
minimal DNA test to see which embryos would be most likely to take.
It's hard to deny this Philadelphia couple the chance to be parents. David Levy and Marybeth Scheidts look very wholesome in their family photo holding their son Connor, born in May 2013. They clearly weren't trying to select the embryo with their preferred hair or eye color or other physical or mental traits. In fact, they didn't even have a full DNA analysis done, only a scan of the chromosomes, the structures that hold genes. This isn't Brave New World-esque test tube babies. It's a traditional family – with the best...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...